Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma

Murakami,Aki; Tabata,Chiharu; Tabata,Rie; Okuwa,Hisaya; Nakano,Takashi

doi:10.3892/ol.2011.536

Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma

Authors:
- Aki Murakami
- Chiharu Tabata
- Rie Tabata
- Hisaya Okuwa
- Takashi Nakano
View Affiliations

Affiliations: Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, Hyogo 663-8501, Japan
Published online on: December 23, 2011 https://doi.org/10.3892/ol.2011.536
Pages: 581-585

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure. MPM exhibits a limited response to conventional chemotherapy and radiotherapy. This, early diagnosis of MPM is essential. Malignant tumor progression requires the destruction of the basement membrane, which is constructed from extracellular matrix (ECM) materials. Various types of human tumor cells are reported to produce ECM-degrading proteases that are important in tumor progression. Among this group of proteolytic enzymes, matrix metalloproteinases (MMPs) are thought to be important due to their wide degrading function. We investigated the pleural effusion MMP-3 levels of patients with MPM and compared them with those of a population with non-malignant pleuritis or lung cancer involving malignant pleural effusion. The pleural effusion MMP-3 concentrations of 52 MPM patients and 67 non-MPM patients were measured. The results showed that the MPM patients had significantly higher pleural effusion MMP-3 levels than the population with non-malignant pleuritis. The overall survival of the MPM patients with lower pleural effusion MMP-3 levels was longer than that of patients with higher pleural effusion MMP-3 levels. Our data therefore suggest a clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma.

View Figures

View References

1	Robinson BW, Musk AW and Lake RA: Malignant mesothelioma. Lancet. 366:397–408. 2005. View Article : Google Scholar : PubMed/NCBI
2	Robinson BW and Lake RA: Advances in malignant mesothelioma. N Engl J Med. 353:1591–1603. 2005. View Article : Google Scholar : PubMed/NCBI
3	Wagner JC, Sleggs CA and Marchand P: Diffuse pleural mesothelioma and asbestos exposure in the North; Western Cape Province. Br J Ind Med. 17:260–271. 1960.PubMed/NCBI
4	Rake C, Gilham C, Hatch J, et al: Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer. 100:1175–1183. 2009. View Article : Google Scholar : PubMed/NCBI
5	Selikoff IJ, Hammond EC and Seidman H: Latency of asbestos disease among insulation workers in the United States and Canada. Cancer. 15:2736–2740. 1980. View Article : Google Scholar : PubMed/NCBI
6	Liotta LA and Stetler-Stevenson WG: Metalloproteinases and cancer invasion. Semin Cancer Biol. 1:99–106. 1990.PubMed/NCBI
7	Johnson LL, Dyer R and Hupe DJ: Matrix metalloproteinase. Curr Opin Chem Biol. 2:466–471. 1998. View Article : Google Scholar
8	Kleiner DE and Stetler-Stevenson WG: Structural biochemistry and activation of matrix metalloproteases. Curr Opin Cell Biol. 5:891–897. 1993. View Article : Google Scholar : PubMed/NCBI
9	Mukherjee S, Roth MJ, Dawsey SM, et al: Increased matrix metalloproteinase activation in esophageal squamous cell carcinoma. J Transl Med. 8:912010. View Article : Google Scholar : PubMed/NCBI
10	Phromnoi K, Yodkeeree S, Anuchapreeda S, et al: Inhibition of MMP-3 activity and invasion of the MDA-MB-231 human invasive breast carcinoma cell line by bioflavonoids. Acta Pharmacol Sin. 30:1169–1176. 2009. View Article : Google Scholar : PubMed/NCBI
11	Lee EJ, Kim SY, Hyun JW, et al: Glycitein inhibits glioma cell invasion through down-regulation of MMP-3 and MMP-9 gene expression. Chem Biol Interact. 185:18–24. 2010. View Article : Google Scholar : PubMed/NCBI
12	Yeh YC, Sheu BS, Cheng HC, et al: Elevated serum matrix metalloproteinase-3 and -7 in H. pylori-related gastric cancer can be biomarkers correlating with a poor survival. Dig Dis Sci. 55:1649–1657. 2010.PubMed/NCBI
13	Okamoto K, Ishida C, Ikebuchi Y, et al: The genotypes of IL-1 beta and MMP-3 are associated with the prognosis of HCV-related hepatocellular carcinoma. Intern Med. 49:887–895. 2010. View Article : Google Scholar : PubMed/NCBI
14	Srivastava P, Mandhani A, Kapoor R, et al: Role of MMP-3 and MMP-9 and their haplotypes in risk of bladder cancer in North Indian cohort. Ann Surg Oncol. 17:3068–3075. 2010. View Article : Google Scholar : PubMed/NCBI
15	Harvey P, Clark IM, Jaurand MC, et al: Hepatocyte growth factor/scatter factor enhances the invasion of mesothelioma cell lines and the expression of matrix metalloproteinases. Br J Cancer. 83:1147–1153. 2000. View Article : Google Scholar : PubMed/NCBI
16	Liu Z, Ivanoff A and Klominek J: Expression and activity of matrix metalloproteases in human malignant mesothelioma cell lines. Int J Cancer. 91:638–643. 2001. View Article : Google Scholar : PubMed/NCBI
17	Rusch VW: A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest. 108:1122–1128. 1995. View Article : Google Scholar : PubMed/NCBI
18	Vogelzang NJ, Rusthoven JJ, Symanowski J, et al: Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 21:2636–2644. 2003. View Article : Google Scholar : PubMed/NCBI
19	Nowak AK, Lake RA, Kindler HL, et al: New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin Oncol. 29:82–96. 2002. View Article : Google Scholar : PubMed/NCBI
20	Pass HI, Lott D, Lonardo F, et al: Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 353:1564–1573. 2005. View Article : Google Scholar : PubMed/NCBI
21	Adachi Y, Aoki C, Yoshio-Hoshino N, et al: Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer. 119:1303–1311. 2006. View Article : Google Scholar : PubMed/NCBI
22	Tabata C, Tabata R, Hirayama N, et al: All-trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice. Eur Respir J. 34:1159–1167. 2009. View Article : Google Scholar : PubMed/NCBI
23	Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, et al: Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. Growth Factors. 11:29–44. 1994. View Article : Google Scholar
24	Marzo AL, Fitzpatrick DR, Robinson BW, et al: Antisense oligonucleotides specific for transforming growth factor beta2 inhibit the growth of malignant mesothelioma both in vitro and in vivo. Cancer Res. 57:3200–3207. 1997.PubMed/NCBI
25	Versnel MA, Claesson-Welsh L, Hammacher A, et al: Human malignant mesothelioma cell lines express PDGF beta-receptors whereas cultured normal mesothelial cells express predominantly PDGF alpha-receptors. Oncogene. 6:2005–2011. 1991.
26	Mórocz IA, Schmitter D, Lauber B, et al: Autocrine stimulation of a human lung mesothelioma cell line is mediated through the transforming growth factor alpha/epidermal growth factor receptor mitogenic pathway. Br J Cancer. 70:850–856. 1994.
27	Galffy G, Mohammed KA, Dowling PA, et al: Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 59:367–371. 1999.PubMed/NCBI
28	Fuhrman C, Duche JC, Chouaid C, et al: Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies. Clin Biochem. 33:405–410. 2000. View Article : Google Scholar : PubMed/NCBI
29	Paganuzzi M, Onetto M, Marroni P, et al: Diagnostic value of CYFRA 21-1 tumor marker and CEA in pleural effusion due to mesothelioma. Chest. 119:1138–1142. 2001. View Article : Google Scholar : PubMed/NCBI
30	Robinson BW, Creaney J, Lake R, et al: Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 362:1612–1616. 2003. View Article : Google Scholar : PubMed/NCBI
31	Frebourg T, Lerebours G, Delpech B, et al: Serum hyaluronate in malignant pleural mesothelioma. Cancer. 59:2104–2107. 1987. View Article : Google Scholar : PubMed/NCBI
32	Schouwink H, Korse CM, Bonfrer JM, et al: Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer. 25:25–32. 1999. View Article : Google Scholar : PubMed/NCBI
33	Creaney J, Yeoman D, Naumoff LK, et al: Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax. 62:569–576. 2007. View Article : Google Scholar : PubMed/NCBI
34	Edwards JG, McLaren J, Jones JL, et al: Matrix metalloproteinases 2 and 9 (gelatinases A and B) expression in malignant mesothelioma and benign pleura. Br J Cancer. 88:1553–1559. 2003. View Article : Google Scholar : PubMed/NCBI
35	Roomi MW, Monterrey JC, Kalinovsky T, et al: Modulation of MMP-2 and MMP-9 by cytokines, mitogens and inhibitors in lung cancer and malignant mesothelioma cell lines. Oncol Rep. 22:1283–1291. 2009.PubMed/NCBI
36	Murphy GJ, Murphy G and Reynolds JJ: The origin matrix metalloproteinases and their familial relationships. FEBS Lett. 289:4–7. 1991. View Article : Google Scholar : PubMed/NCBI